BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» BioCryst Monetizes Peramivir Payments in $30M Financing
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
BioCryst Monetizes Peramivir Payments in $30M Financing
March 11, 2011
By
Marie Powers
No Comments
BioCryst Pharmaceuticals Inc. took an inventive tack to raise $30 million this week by monetizing payments from licensee Shionogi & Co. Ltd., of Osaka, Japan, for peramivir (Rapiacta), a neuraminidase inhibitor for the treatment of influenza.
BioWorld